61 results about "Pigmented Epithelium" patented technology

The systems and methods described herein provide improved techniques for displaying imaging markers for verifying biometry. A method includes receiving an indication to initiate a first optical coherence tomography (OCT) scanning of an eye; initiating, based on the received indication, the first OCT scanning of the eye; generating, based on the first OCT scanning, a first OCT image of the eye; detecting, based on the first OCT image, a retinal pigment epithelium (RPE) and a fovea in the eye; based on the detecting, causing a first enhanced OCT image to be displayed to a user, the first enhanced OCT image displaying: a first virtual marker segmenting at least a portion of the detected RPE, and a second virtual marker, where the second virtual marker visually identifies a location of the detected fovea, and where the second virtual marker is a radial line through the location of the detected fovea.

The invention provides an establishment method and application of a non-human primate retinal pigment epithelium injury model, and belongs to the field of animal models. The method comprises the following steps: (1) performing anesthesia and mydriasis on a non-human primate; (2) attaching a full retinoscope to the cornea, and adjusting a slit lamp so that an operator can observe the macular fovea centralis, optic disc and upper and lower vascular arches of the non-human primate; and (3) carrying out photocoagulation on the photocoagulation area by using a laser photocoagulator, and ending the photocoagulation until 250-300 primary light spots appear in the photocoagulation area. The invention provides a method for constructing a non-human primate retinal pigment epithelium (RPE) injury model by using laser by taking a non-human primate as a model animal for the first time. The model forming rate of the RPE injury animal model constructed by the invention is stable, the injury caused by the RPE injury animal model is irreversible, and a stable animal disease model is provided for clinical research and development of new drugs related to dry age-related macular degeneration caused by RPE injury.

The present invention relates to a method of differentiating an induced pluripotent stem cell into a retinal pigment epithelial cell. Additionally, the present invention relates to a retinal pigment epithelial cell culture obtainable by the differentiation method and a retinal pigment epithelial cell culture obtained by the differentiation method. In addition, the present invention concerns a retinal pigment epithelium consisting of or comprising a retinal pigment epithelial cell culture obtainable or obtained by the differentiation method. The present invention also relates to a pharmaceutical composition comprising a retinal pigment epithelial cell culture obtained by the differentiation method. The present invention concerns a method of treating a retinal degenerative disease in a subject, comprising administering to a subject a retinal pigment epithelial cell differentiated from the induced pluripotent stem cell by the method. Finally, the present invention also refers to an in vivo method of detecting the survival rate of a retinal pigment epithelial cell differentiated from an induced pluripotent stem cell by the defined method in a subject and an in vitro method of determining the immunogenicity of said retinal pigment epithelial cell differentiated from an induced pluripotent stem cell by the defined method in said subject, to whom said differentiated RPE cell has been pre-delivered.

The invention relates to the technical field of retina analysis, and discloses a fundus optical coherence tomography image feature point automatic positioning method, which comprises the following steps: acquiring optical coherence tomography images of a fundus disease patient at different disease course stages, constructing an image database containing a training set and a verification set, and determining the feature points of the fundus optical coherence tomography image on the basis of the image database. And carrying out feature layer segmentation on the image by adopting a U-Net convolutional neural network. And determining a blood vessel shadow position in the fundus optical coherence tomography image and acquiring a boundary of the blood vessel shadow position based on the pigment epithelium gray scale curve. And determining the position of a seed point and the size of a subarea by combining an important layer boundary and a vessel shadow boundary, and assisting digital image correlation to realize retina full-field deformation measurement. According to the method, through deep fusion of deep learning and an image processing technology, the problem of automatic selection of the seed points in the fundus OCT image is solved, the efficiency, precision and reliability of retinal deformation measurement are remarkably improved, and a powerful technical tool is provided for mechanism research and clinical diagnosis and treatment of fundus diseases.

Disclosed is chemical compounds C that are derivatives of norbixin and have tropism for the eye, and are intended to be used in the treatment of eye diseases in mammals, in particular in the context of altering the retinal pigment epithelium and more particularly in the context of age-related macular degeneration (AMD) and Stargardt's disease.

To provide a pharmaceutical composition for restoring lysosomal function of retinal pigment epithelial cells.SOLUTION: Provided is a pharmaceutical composition for restoring lysosomal function of retinal pigment epithelial (RPE) cells in a subject, comprising a polypeptide comprising βA1-crystallin or a nucleic acid encoding the polypeptide.SELECTED DRAWING: Figure 1

The invention belongs to the field of RPE cell preparations, and relates to a retinal pigment epithelial cell spherical preparation which is obtained by the following steps: step 1, obtaining RPE cells; and 2, inoculating the RPE cells into a cell culture plate by using an inoculation culture medium, and culturing after centrifugal precipitation, so that a plurality of RPE cells are aggregated to form RPE cell balls with uniform sizes. The cell preparation form obtained by the scheme not only can avoid injection leakage of the subretinal space, but also has the advantages of being convenient to inject and uniform in cell expansion, so that preclinical needs are met, and an important basis is provided for preparation of a clinical-grade RPE cell preparation and subsequent further development of clinical research.

To provide compositions containing RPE cells or RPE monolayers, as well as methods and materials for making RPE cells or RPE monolayers from, for example, stem cells (e.g., iPSCs).SOLUTION: Disclosed is a method for making a retinal pigment epithelium monolayer, the method comprising, or consisting essentially of, culturing stem cells in a container having a surface coated with fibrinogen, wherein the surface is coated with greater than 3 μg / mL of fibrinogen, wherein the cells are in contact with the fibrinogen, and wherein the cells form the retinal pigment epithelium monolayer.SELECTED DRAWING: None

The invention discloses application of a DKK1 inhibitor in preparation of a medicine for treating dry age-related macular degeneration. According to the application disclosed by the invention, the expression of DKK1 in dry AMD cells and animal models induced by sodium iodate (NaIO3) is obviously improved. The form of the retinal pigment epithelial cells can be protected and the death rate can be reduced by using the siRNA of the targeted DKK1 in an in-vitro experiment, and the plaque loss of the retinal pigment epithelial cells can be relieved and the retinal pigment epithelial cells can be protected by using the shRNA of the targeted DKK1 in an in-vivo experiment. Therefore, the invention provides a new therapeutic target and therapeutic strategy for dry AMD, and has important clinical application value.

The present invention relates to a composition for preventing and alleviating or treating glaucoma and macular degeneration, containing a Centella asiatica extract. Particularly, the composition increases the glucose metabolism efficiency of cells so as to increase the survival rate of retinal neurons and pigment epithelial cells and protects cells from oxidative damage caused by A2E, thereby being effectively usable as a composition for eye health and for preventing and alleviating or treating glaucoma and macular degeneration.

Provided are a production method of retinal pigment epithelial (RPE) cells that improves differentiation induction efficiency of pluripotent stem cells into RPE cells, and can provide highly pure RPE cells by a simple and easy operation in a short period, a culture method of RPE cells that can stably grow and culture a cell, a toxicity / efficacy evaluation method using RPE cells useful for transplantation therapy, and a therapeutic drug for a retinal disease. The invention relates to a production method of RPE cells, comprising adhesion culture of human pluripotent stem cells using a culture substrate coated with a laminin-E8 fragment, a culture method of RPE cells, comprising adhesion culture of RPE cells using a culture substrate coated with a laminin-E8 fragment, a toxicity or efficacy evaluation method using RPE cells obtained by producing or culturing by the method, and a therapeutic drug for a retinal disease, containing the RPE cells.

The present invention provides a method for preparing retinal pigment epithelial cells, comprising (1) a first step of subjecting pluripotent stem cells to suspension culture in a serum-free medium to form aggregates of the pluripotent stem cells, (2) a second step of subjecting the aggregates of the pluripotent stem cells to suspension culture in a serum-free medium to form aggregates of the pluripotent stem cells. (1) a third step in which the aggregate formed in step (1) is subjected to suspension culture in a serum-free medium or a serum-containing medium, each of which does not contain a substance acting on the Sonic hedgehog signal transduction pathway and contains a substance acting on the BMP signal transduction pathway, to obtain an aggregate containing retinal progenitor cells; the aggregate formed in step (2) is subjected to suspension culture in a serum-free medium or a serum-containing medium that does not contain a substance that acts on the Sonic hedgehog signal transduction pathway and a substance that acts on the BMP signal transduction pathway, but contains a substance that acts on the Wnt signal pathway, thereby obtaining an aggregate containing retinal pigment epithelium cells.

The present invention addresses the problem of providing an inhibitor for retinochoroidal disorders, in particular, an inhibitor for retinochoroidal scar formation and retinochoroidal atrophy in an epiretinal, intraretinal or subretinal tissue. This problem can be solved by preparing an inhibitor for retinochoroidal disorders which comprises, as an active ingredient, (E)-4-(2-{3-[(1H-pyrazol-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid, an ester thereof or a salt of the same. The inhibitor for retinochoroidal disorders can inhibit collagen atrophy of retinal pigment epithelium cells, fibroblasts, glial cells and the like and thus inhibit retinochoroidal disorders.

The present invention provides a method for preparing retinal pigment epithelial cells, comprising the following steps: (1) a first step of culturing pluripotent stem cells in a culture medium containing at least one selected from the group consisting of an FGF receptor inhibitor and a MEK inhibitor for a period of no more than 30 days, and (2) a second step of culturing the cells obtained in the first step in a culture medium containing at least one selected from the group consisting of a Rho signal transduction pathway inhibitor and a cell apoptosis inhibitor to form retinal pigment epithelial cells. Using this method, it is possible to prepare retinal pigment epithelial cells from pluripotent stem cells in a more efficient and convenient manner.

The present invention is directed to compositions for treating oxidative-stress related-damage of retinal pigment epithelium (RPE) cells by contacting orbital fat-derived mesenchymal cell with the damaged RPE cells.

The invention discloses an application of CRX in inhibition of epithelial-mesenchymal transition of retinal pigment epithelial cells. The invention discloses an application of CRX in preparation of a medicine as shown in (1) or (2). The medicine comprises a carrier for over-expressing CRX; (1) a drug for inhibiting epithelial-mesenchymal transition of retinal pigment epithelial cells; and (2) a medicine for preventing and / or treating age-related macular degeneration subretinal fibrosis. The invention finds that the expression of E-cadherin and Occludin can be promoted by overexpressing CRX in RPE cells, so that the epithelial-mesenchymal transition of the RPE cells is inhibited, and the CRX can be used for preventing or treating age-related macular degeneration subretinal fibrosis and also can be used for preventing or treating highly myopia retinal degeneration.

The invention belongs to the field of natural products, and provides chrysanthemum essential oil with a function of improving dry age-related macular degeneration. The chrysanthemum essential oil contains up to 168 compounds, more comprehensive biological activity support is provided for treatment, experiments prove that the essential oil can significantly optimize the retina structure of macular mice, specifically, the inner nuclear layer and the outer nuclear layer are closely arranged, the total thickness of the retina is significantly increased, the retinal pigment epithelium is more closely arranged, and the effect of improving the retina structure is achieved. Therefore, the polypeptide has the potential of improving the dry age-related macular degeneration function.

The present invention relates to an eye drop composition for preventing or treating eye neovascular diseases, comprising collagen type I and a pigment epithelium-derived factor peptide as active ingredients. The present invention provides an eye drop composition capable of most stably storing for a long period of time a pigment epithelium-derived factor peptide, which is an active ingredient exhibiting an anti-neovascular effect on ocular neovascular diseases, and as it is confirmed that the eye drop composition, according to the present invention, exhibits a therapeutic or ameliorating effect on ocular neovascular diseases even when the eye drop composition contains a low concentration of a pigment epithelium-derived factor (PEDF) peptide represented by SEQ ID NO: 1, which is an active ingredient, the present invention provides the eye drop composition exhibiting a therapeutic or ameliorating effect on ocular neovascular diseases and having excellent storage stability.

To provide a tissue replacement implant that is clinically effective for treatment of a variety of retinal diseases and retinal dysfunction, and can be produced using Good Manufacturing Practice (GMP) / clinical-grade manufacturing, and a method of treating a subject.SOLUTION: Tissue replacement implants are provided that include polarized retinal pigment epithelial cells on a poly(lactic-co-glycolic acid) (PLGA) scaffold. The PLGA scaffold is 20-30 microns in thickness, and has a DL-lactide / glycotide ratio of about 1:1, an average pore size of less than about 1 micron, and a fiber diameter of about 150 to about 650 nm.SELECTED DRAWING: None

The invention relates to a compatibility method of a retinal pigment epithelial cell cryopreservation preparation, which comprises the steps of dilution, balancing, washing and compatibility: 1) a dilution step: preparing a diluted solution which comprises a balanced salt solution (for perfusion), preferably, the diluted solution further comprises a compound amino acid injection; 2) a balancing step: resuscitating cells in the RPE cell cryopreservation preparation, then mixing the cells with the prepared diluted solution, and standing for balancing; (3) washing: centrifuging the solution, absorbing and discarding the supernate, adding a balanced salt solution (for perfusion), resuspending the cells, centrifuging, and absorbing and discarding the supernate; and 4) a compatibility step: adding a balanced salt solution (for perfusion) into the cell precipitate, and adjusting the cell to a required density according to a living cell density result.

The present invention discloses an OCT image stratification and lesion semantic segmentation method, device and storage medium. The method comprises: obtaining each BScan two-dimensional slice image data of OCT of one eye of a patient to be examined; inputting the slice image data one by one into a pre-trained first-stage convolutional neural network to obtain the first-stage stratification, optic disc area, and semantic segmentation prediction results of the macula fovea area; making a "region of interest" according to the obtained first-stage stratification, optic disc area, and semantic segmentation prediction results of the macula fovea area; obtaining a data map of the "region of interest"; inputting the data map of the "region of interest" into a second-stage convolutional neural network to obtain the second-stage stratification, drusen, pigment epithelial detachment, and semantic segmentation prediction results of choroidal neovascularization lesions. The present invention increases the proportion of lesion pixels to total pixels and reduces the learning difficulty of small-area positive lesions such as drusen.

The recombinant AAV capsid protein is characterized in that the recombinant AAV capsid protein is obtained by mutating a common region of natural AAV5 capsid proteins VP1, VP2 and VP3; or the natural AAV5 capsid protein is heterozygous with other AAV serotype capsids, and then a common region of VP1, VP2 and VP3 is mutated, wherein the mutation point corresponds to at least one mutation from the 310th site to the 736th site of the AAV5 capsid protein of SEQ ID NO: 1; the capsid protein is targeted to the retinal pigment epithelium through intravitreal delivery, the problems that in the prior art, delivery is difficult, and retinal pigment epithelium cells cannot be effectively transduced are solved, and the AAV capsid protein has high transduction rate and immune escape capacity.

Provided are compositions containing microalgae extracellular vesicles (MEVs) formulated for administration to the eye for treatment of diseases, disorders, and conditions of the eye, particularly for diseases, disorders, and conditions that involve tissues and cells in the back of the eye, which generally cannot be treated with eyedrops. Upon administration to the eye, the MEVs deliver therapeutics to tissues that include the choroid, retinal pigment epithelium cells, and photoreceptor cells. The compositions contain extracellular vesicles from microalgae (MEVs) that are loaded with bioactive cargo for treating or diagnosing or monitoring a disease, disorder, or condition of the eye or involving the eye. Methods of treatment of diseases, disorders, and conditions of the eye are provided.

The present invention relates to a method for identifying and detecting the expression of biomarkers present in choroidal and retinal pigmented epithelium disorders or in ocular angiogenic, epithelial and neuronal disorders. The invention further encompasses a kit for biomarker identification and uses thereof. The present invention pertains to the field of chemical biology, more specifically in the healthcare sector, and describes a method for identifying and detecting the expression of a set of biomarkers present in severe ophthalmological diseases.

To provide compositions for protecting retina which can protect retinal pigment epithelial cells from the damage of active oxygen more effectively and inhibit retinopathy.SOLUTION: A composition for protecting retina contains as active ingredients astaxanthin and at least one ingredient selected from the group consisting of Ipomoea batatas young-leaf processed materials, Pueraria montana flower processed materials, Vaccinium myrtillus processed materials, gallic acid, glutamic acid, histidine, methionine, serine, tyrosine, valine, vitamin B6, vitamin B12, vitamin C, vitamin D3, vitamin K, a calcium compound, a zinc compound, an iron compound, a molybdenum compound, a chromium compound, and shellac.SELECTED DRAWING: Figure 1

The application discloses application of TAPI-1 in preparation of a drug for treating dry age-related macular degeneration, and belongs to the technical field of biological medicine. A dry age-related macular degeneration mouse model is constructed by using sodium iodate, and a TAPI-1 solution is injected into the vitreous body for treatment, and structural examination and histopathological examination are conducted on the mouse. The experimental results show that, compared with the control group, the retinal choroid structure of the mouse treated by TAPI-1 is more complete, the fundus lesion area is less, the damage degree of the pigment epithelium and the photoreceptor cell is lighter, and the expression level of the inflammatory molecules in the ocular tissue is lower, and the treatment effect is significant. The application firstly proposes that TAPI-1 is used for preparing a drug for treating and / or preventing dry age-related macular degeneration, a new treatment strategy is provided for the dry age-related macular degeneration, and the application has a wide application prospect.

The invention discloses an application of erlotinib in preparation of an integrated drug for promoting retinal pigment epithelial cell transplantation. It is found that human embryo RPE cells (human fRPE, hfRPE) transplanted to the subretinal space of a mouse specifically express EGFR, and after erlotinib intragastric administration (40mg / kg) treatment is performed on the mouse, it is observed that under the condition that an immunosuppressive agent is not used, xenogeneic donor cells can be better expanded in the subretinal space of the host and integrated into the RPE cells of the host, tight connection is formed, and therefore the immunosuppressive effect is achieved. Meanwhile, the RPE65 functional protein is stably expressed. Under the treatment of the erlotinib with the concentration, the integrity of tissue structures (retinal pigment epithelial cells, photoreceptor extracellular nodes and the like) of a subretinal space is not influenced.

A method for reinforcing a cellularized retinal construct fabricated from (i) endothelial cells; (ii) retinal pigment epithelial cells and / or photoreceptors; and (iii) an extracellular matrix (ECM) hydrogel is disclosed. The method comprises contacting the construct with a biocompatible small-molecule reinforcing agent that is capable of chemically interacting with the ECM hydrogel under conditions that maintain viability of the cells, to thereby increase a compressive modulus of the ECM hydrogel by at least 10%.

The invention relates to a method for differentiating induced pluripotent stem cells into retinal pigment epithelial cells. In addition, the present invention relates to a retinal pigment epithelial cell culture obtainable by the differentiation method and a retinal pigment epithelial cell culture obtained by the differentiation method. Furthermore, the present invention relates to retinal pigment epithelium consisting of or comprising a retinal pigment epithelium cell culture obtainable or obtained by said differentiation method. The invention also relates to a pharmaceutical composition comprising a retinal pigment epithelial cell culture obtained by said differentiation method. The present invention relates to a method of treating a retinal degenerative disease in a subject, the method comprising administering to the subject retinal pigment epithelial cells differentiated from induced pluripotent stem cells by the method. Finally, the invention also relates to an in vivo method for detecting the survival rate of retinal pigment epithelial cells in a subject, said retinal pigment epithelial cells being differentiated from induced pluripotent stem cells by a defined method, and to an in vitro method for determining the immunogenicity of retinal pigment epithelial cells in a subject, the retinal pigment epithelial cells are differentiated from induced pluripotent stem cells by a defined method, the differentiated RPE cells having been pre-delivered to the subject.

Disclosed are methods for preparing retinal pigment epithelium (RPE) cells from pluripotent stem cells (PSCs). More particularly, it represents an automated method that combines in a sequential manner three differentiating agents to direct the differentiation of human PSCs into RPE cells.